Human Microbiome Project, C. Structure, function and diversity of the healthy human microbiome. Nature 486, 207–214 (2012).
Charlson, E. S. et al. Disordered microbial communities in the upper respiratory tract of cigarette smokers. PLoS ONE 5, e15216 (2010).
Erb-Downward, J. R. et al. Analysis of the lung microbiome in the “healthy” smoker and in copd. PLoS ONE 6, e16384 (2011).
Orgiazzi, A. et al. 454 pyrosequencing analysis of fungal assemblages from geographically distant, disparate soils reveals spatial patterning and a core mycobiome. Diversity 5, 73–98 (2013).
Hooper, L. V. et al. Molecular analysis of commensal host-microbial relationships in the intestine. Science 291, 881–884 (2001).
Marchesi, J. R. & Ravel, J. The vocabulary of microbiome research: a proposal. Microbiome 3, 31 (2015).
Johnson, J. S. et al. Evaluation of 16s rrna gene sequencing for species and strain-level microbiome analysis. Nat. Commun. 10, 5029 (2019).
Toma, I. et al. Single-molecule long-read 16s sequencing to characterize the lung microbiome from mechanically ventilated patients with suspected pneumonia. J. Clin. Microbiol. 52, 3913–3921 (2014).
Dickson, R. P. et al. Spatial variation in the healthy human lung microbiome and the adapted island model of lung biogeography. Ann. Am. Thorac. Soc. 12, 821–830 (2015).
Yu, G. et al. Characterizing human lung tissue microbiota and its relationship to epidemiological and clinical features. Genome Biol. 17, 163 (2016).
Yun, Y. et al. Environmentally determined differences in the murine lung microbiota and their relation to alveolar architecture. PLoS ONE 9, e113466 (2014).
Wang, Z. et al. Multi-omic meta-analysis identifies functional signatures of airway microbiome in chronic obstructive pulmonary disease. ISME J. 14, 2748–2765 (2020).
Wang, Z. et al. Inflammatory endotype-associated airway microbiome in chronic obstructive pulmonary disease clinical stability and exacerbations: a multicohort longitudinal analysis. Am. J. Respir. Crit. Care Med. 203, 1488–1502 (2021).
Einarsson, G. G. et al. Community dynamics and the lower airway microbiota in stable chronic obstructive pulmonary disease, smokers and healthy non-smokers. Thorax 71, 795–803 (2016).
Whiteside, S. A., McGinniss, J. E. & Collman, R. G. The lung microbiome: Progress and promise. J. Clin. Invest. 131, e150473 (2021).
Dickson, R. P. et al. Enrichment of the lung microbiome with gut bacteria in sepsis and the acute respiratory distress syndrome. Nat. Microbiol. 1, 16113 (2016).
Yang, L. et al. Alterations in oral microbiota in hiv are related to decreased pulmonary function. Am. J. Respir. Crit. Care Med. 201, 445–457 (2020).
Natalini, J. G., Singh, S. & Segal, L. N. The dynamic lung microbiome in health and disease. Nat. Rev. Microbiol. 21, 222–235 (2023).
Beck, J. M. et al. Multicenter comparison of lung and oral microbiomes of hiv-infected and hiv-uninfected individuals. Am. J. Respir. Crit. Care Med. 192, 1335–1344 (2015).
Scher, J. U. et al. The lung microbiota in early rheumatoid arthritis and autoimmunity. Microbiome 4, 60 (2016).
Baker, J. M. et al. Whole lung tissue is the preferred sampling method for amplicon-based characterization of murine lung microbiota. Microbiome 9, 99 (2021).
Pattaroni, C. et al. Early-life formation of the microbial and immunological environment of the human airways. Cell Host Microbe 24, 857–865.e854 (2018).
Gronseth, R. et al. Protected sampling is preferable in bronchoscopic studies of the airway microbiome. ERJ Open Res. 3, 00019–2017 (2017).
Liu, H. X. et al. Difference of lower airway microbiome in bilateral protected specimen brush between lung cancer patients with unilateral lobar masses and control subjects. Int. J. Cancer 142, 769–778 (2018).
Noverr, M. C., Noggle, R. M., Toews, G. B. & Huffnagle, G. B. Role of antibiotics and fungal microbiota in driving pulmonary allergic responses. Infect. Immun. 72, 4996–5003 (2004).
Gore, C. et al. Bifidobacterium pseudocatenulatum is associated with atopic eczema: a nested case-control study investigating the fecal microbiota of infants. J. Allergy Clin. Immunol. 121, 135–140 (2008).
Hilty, M. et al. Disordered microbial communities in asthmatic airways. PLoS ONE 5, e8578 (2010).
McDonough, J. E. et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary disease. N. Engl. J. Med. 365, 1567–1575 (2011).
Fodor, A. A. et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS ONE 7, e45001 (2012).
Pragman, A. A., Kim, H. B., Reilly, C. S., Wendt, C. & Isaacson, R. E. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS ONE 7, e47305 (2012).
Segal, L. N. et al. Enrichment of lung microbiome with supraglottic taxa is associated with increased pulmonary inflammation. Microbiome 1, 19 (2013).
Huang, Y. J. et al. Airway microbiota and bronchial hyperresponsiveness in patients with suboptimally controlled asthma. J. Allergy Clin. Immunol. 127, 372–381 e371-373 (2011).
Boyton, R. J., Reynolds, C. J., Quigley, K. J. & Altmann, D. M. Immune mechanisms and the impact of the disrupted lung microbiome in chronic bacterial lung infection and bronchiectasis. Clin. Exp. Immunol. 171, 117–123 (2013).
Lobo, L. J. & Noone, P. G. Respiratory infections in patients with cystic fibrosis undergoing lung transplantation. Lancet Respir. Med. 2, 73–82 (2014).
Borewicz, K. et al. Longitudinal analysis of the lung microbiome in lung transplantation. FEMS Microbiol. Lett. 339, 57–65 (2013).
Nguyen, L. D., Viscogliosi, E. & Delhaes, L. The lung mycobiome: an emerging field of the human respiratory microbiome. Front. Microbiol. 6, 89 (2015).
Segal, L. N. & Dickson, R. P. The lung microbiome in hiv. Getting to the haart of the host-microbe interface. Am. J. Respir. Crit. Care Med. 194, 136–137 (2016).
Hong, B. Y. et al. Microbiome changes during tuberculosis and antituberculous therapy. Clin. Microbiol. Rev. 29, 915–926 (2016).
Huang, Y. et al. Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 196, 208–219 (2017).
Dickson, R. P. The lung microbiome and ards. It is time to broaden the model. Am. J. Respir. Crit. Care Med. 197, 549–551 (2018).
O’Dwyer, D. N. et al. Lung dysbiosis, inflammation, and injury in hematopoietic cell transplantation. Am. J. Respir. Crit. Care Med. 198, 1312–1321 (2018).
McVerry, B. J. & Morris, A. The lung microbiome in hematopoietic stem cell transplant. Where the money lies. Am. J. Respir. Crit. Care Med. 198, 1249–1251 (2018).
Kullberg, R. F. J. et al. Lung microbiota of critically ill patients with covid-19 are associated with nonresolving acute respiratory distress syndrome. Am. J. Respir. Crit. Care Med. 206, 846–856 (2022).
Whiteside, S. A., Razvi, H., Dave, S., Reid, G. & Burton, J. P. The microbiome of the urinary tract–a role beyond infection. Nat. Rev. Urol. 12, 81–90 (2015).
Huffnagle, G. B., Dickson, R. P. & Lukacs, N. W. The respiratory tract microbiome and lung inflammation: a two-way street. Mucosal Immunol. 10, 299–306 (2017).
Lagkouvardos, I., Overmann, J. & Clavel, T. Cultured microbes represent a substantial fraction of the human and mouse gut microbiota. Gut Microbes 8, 493–503 (2017).
Lagier, J. C. et al. Culture of previously uncultured members of the human gut microbiota by culturomics. Nat. Microbiol. 1, 16203 (2016).
Dickson, R. P. et al. Bacterial topography of the healthy human lower respiratory tract. mBio 8, e02287–16 (2017).
Gleeson, K., Eggli, D. F. & Maxwell, S. L. Quantitative aspiration during sleep in normal subjects. Chest 111, 1266–1272 (1997).
Chotirmall, S. H. et al. Microbiomes in respiratory health and disease: an asia-pacific perspective. Respirology 22, 240–250 (2017).
Pragman, A. A. et al. The lung tissue microbiota of mild and moderate chronic obstructive pulmonary disease. Microbiome 6, 7 (2018).
Charlson, E. S. et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am. J. Respir. Crit. Care Med. 184, 957–963 (2011).
Morris, A. et al. Comparison of the respiratory microbiome in healthy nonsmokers and smokers. Am. J. Respir. Crit. Care Med. 187, 1067–1075 (2013).
Belkaid, Y. & Hand, T. W. Role of the microbiota in immunity and inflammation. Cell 157, 121–141 (2014).
Hooper, L. V., Littman, D. R. & Macpherson, A. J. Interactions between the microbiota and the immune system. Science 336, 1268–1273 (2012).
Ivanov, I. I. et al. Induction of intestinal th17 cells by segmented filamentous bacteria. Cell 139, 485–498 (2009).
Segal, L. N. et al. Enrichment of the lung microbiome with oral taxa is associated with lung inflammation of a th17 phenotype. Nat. Microbiol. 1, 16031 (2016).
Dickson, R. P. et al. The lung microbiota of healthy mice are highly variable, cluster by environment, and reflect variation in baseline lung innate immunity. Am. J. Respir. Crit. Care Med. 198, 497–508 (2018).
Carney, S. M. et al. Methods in lung microbiome research. Am. J. Respir. Cell Mol. Biol. 62, 283–299 (2020).
Cui, L., Morris, A. & Ghedin, E. The human mycobiome in health and disease. Genome Med. 5, 63 (2013).
Huffnagle, G. B. & Noverr, M. C. The emerging world of the fungal microbiome. Trends Microbiol. 21, 334–341 (2013).
Iliev, I. D. et al. Interactions between commensal fungi and the c-type lectin receptor dectin-1 influence colitis. Science 336, 1314–1317 (2012).
Marsland, B. J. & Gollwitzer, E. S. Host-microorganism interactions in lung diseases. Nat. Rev. Immunol. 14, 827–835 (2014).
Carmody, L. A. et al. Changes in cystic fibrosis airway microbiota at pulmonary exacerbation. Ann. Am. Thorac. Soc. 10, 179–187 (2013).
Lim, Y. W. et al. Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. J. Clin. Microbiol. 52, 425–437 (2014).
Delhaes, L. et al. The airway microbiota in cystic fibrosis: A complex fungal and bacterial community–implications for therapeutic management. PLoS ONE 7, e36313 (2012).
Huang, C. et al. Fungal and bacterial microbiome dysbiosis and imbalance of trans-kingdom network in asthma. Clin. Transl. Allergy 10, 42 (2020).
Sharma, A. et al. Associations between fungal and bacterial microbiota of airways and asthma endotypes. J. Allergy Clin. Immunol. 144, 1214–1227.e1217 (2019).
Charlson, E. S. et al. Assessing bacterial populations in the lung by replicate analysis of samples from the upper and lower respiratory tracts. PLoS ONE 7, e42786 (2012).
Ghannoum, M. A. et al. Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. PLoS Pathog. 6, e1000713 (2010).
Hulin, M. et al. Positive associations between respiratory outcomes and fungal index in rural inhabitants of a representative sample of french dwellings. Int. J. Hyg. Environ. Health 216, 155–162 (2013).
Kieninger, E. et al. High rhinovirus burden in lower airways of children with cystic fibrosis. Chest 143, 782–790 (2013).
Dupuy, A. K. et al. Redefining the human oral mycobiome with improved practices in amplicon-based taxonomy: discovery of malassezia as a prominent commensal. PLoS ONE 9, e90899 (2014).
Knutsen, A. P. et al. Fungi and allergic lower respiratory tract diseases. J. Allergy Clin. Immunol. 129, 280–291 (2012). quiz 292-283.
Duran-Pinedo, A. E. et al. Community-wide transcriptome of the oral microbiome in subjects with and without periodontitis. ISME J. 8, 1659–1672 (2014).
Chen, T. C., Chen, Y. H., Chen, Y. C. & Lu, P. L. Fluconazole exposure rather than clonal spreading is correlated with the emergence of candida glabrata with cross-resistance to triazole antifungal agents. Kaohsiung J. Med. Sci. 28, 306–315 (2012).
Bousquet, A. et al. An 8-year survey of strains identified in blood cultures in a clinical haematology unit. Clin. Microbiol. Infect. 20, O7–O12 (2014).
Sepich-Poore, G. D. et al. The microbiome and human cancer. Science 371, eabc4552 (2021).
Dohlman, A. B. et al. A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. Cell 185, 3807–3822.e3812 (2022).
Huang, Y. J. Asthma microbiome studies and the potential for new therapeutic strategies. Curr. Allergy Asthma Rep. 13, 453–461 (2013).
Findley, K. et al. Topographic diversity of fungal and bacterial communities in human skin. Nature 498, 367–370 (2013).
Reyes, A. et al. Viruses in the faecal microbiota of monozygotic twins and their mothers. Nature 466, 334–338 (2010).
Liang, G. & Bushman, F. D. The human virome: assembly, composition and host interactions. Nat. Rev. Microbiol. 19, 514–527 (2021).
Pride, D. T. et al. Evidence of a robust resident bacteriophage population revealed through analysis of the human salivary virome. ISME J. 6, 915–926 (2012).
Lysholm, F. et al. Characterization of the viral microbiome in patients with severe lower respiratory tract infections, using metagenomic sequencing. PLoS ONE 7, e30875 (2012).
Willner, D. et al. Metagenomic analysis of respiratory tract DNA viral communities in cystic fibrosis and non-cystic fibrosis individuals. PLoS ONE 4, e7370 (2009).
van den Bergh, M. R. et al. Associations between pathogens in the upper respiratory tract of young children: Interplay between viruses and bacteria. PLoS ONE 7, e47711 (2012).
Abbas, A. A. et al. Redondoviridae, a family of small, circular DNA viruses of the human oro-respiratory tract associated with periodontitis and critical illness. Cell Host Microbe 25, 719–729.e714 (2019).
Wang, Y. et al. Metagenomic analysis of viral genetic diversity in respiratory samples from children with severe acute respiratory infection in china. Clin. Microbiol. Infect. 22, 458.e451–458.e459 (2016).
Taboada, B. et al. Is there still room for novel viral pathogens in pediatric respiratory tract infections? PLoS ONE 9, e113570 (2014).
Virgin, H. W., Wherry, E. J. & Ahmed, R. Redefining chronic viral infection. Cell 138, 30–50 (2009).
Popgeorgiev, N., Temmam, S., Raoult, D. & Desnues, C. Describing the silent human virome with an emphasis on giant viruses. Intervirology 56, 395–412 (2013).
Duerkop, B. A. & Hooper, L. V. Resident viruses and their interactions with the immune system. Nat. Immunol. 14, 654–659 (2013).
Young, J. C. et al. Viral metagenomics reveal blooms of anelloviruses in the respiratory tract of lung transplant recipients. Am. J. Transpl. 15, 200–209 (2015).
Stewart, C. J. et al. Respiratory syncytial virus and rhinovirus bronchiolitis are associated with distinct metabolic pathways. J. Infect. Dis. 217, 1160–1169 (2018).
MacDuff, D. A. et al. Phenotypic complementation of genetic immunodeficiency by chronic herpesvirus infection. Elife 4, e04494 (2015).
Sun, L. et al. Type i interferons link viral infection to enhanced epithelial turnover and repair. Cell Host Microbe 17, 85–97 (2015).
Barton, E. S., White, D. W. & Virgin, H. W. Herpesvirus latency and symbiotic protection from bacterial infection. Viral Immunol. 22, 3–4,author reply 5-6 (2009).
Lim, Y. W. et al. Metagenomics and metatranscriptomics: Windows on cf-associated viral and microbial communities. J. Cyst. Fibros. 12, 154–164 (2013).
Dickson, R. P., Erb-Downward, J. R. & Huffnagle, G. B. Towards an ecology of the lung: New conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir. Med. 2, 238–246 (2014).
Lamont, R. J., Koo, H. & Hajishengallis, G. The oral microbiota: dynamic communities and host interactions. Nat. Rev. Microbiol. 16, 745–759 (2018).
Abeles, S. R., Ly, M., Santiago-Rodriguez, T. M. & Pride, D. T. Effects of long term antibiotic therapy on human oral and fecal viromes. PLoS ONE 10, e0134941 (2015).
Abeles, S. R. & Pride, D. T. Molecular bases and role of viruses in the human microbiome. J. Mol. Biol. 426, 3892–3906 (2014).
Noverr, M. C., Falkowski, N. R., McDonald, R. A., McKenzie, A. N. & Huffnagle, G. B. Development of allergic airway disease in mice following antibiotic therapy and fungal microbiota increase: role of host genetics, antigen, and interleukin-13. Infect. Immun. 73, 30–38 (2005).
Mukherjee, P. K. et al. Oral mycobiome analysis of hiv-infected patients: Identification of pichia as an antagonist of opportunistic fungi. PLoS Pathog. 10, e1003996 (2014).
Durack, J. et al. Bacterial biogeography of adult airways in atopic asthma. Microbiome 6, 104 (2018).
Bassis, C. M. et al. Analysis of the upper respiratory tract microbiotas as the source of the lung and gastric microbiotas in healthy individuals. mBio 6, e00037 (2015).
Dong, J. et al. Relationships between oral microecosystem and respiratory diseases. Front. Mol. Biosci. 8, 718222 (2021).
Dickson, R. P., Erb-Downward, J. R. & Huffnagle, G. B. Homeostasis and its disruption in the lung microbiome. Am. J. Physiol. Lung Cell Mol. Physiol. 309, L1047–L1055 (2015).
Saeedi, P., Salimian, J., Ahmadi, A. & Imani Fooladi, A. A. The transient but not resident (tbnr) microbiome: a yin yang model for lung immune system. Inhal. Toxicol. 27, 451–461 (2015).
Wu, H. et al. Surfactant proteins a and d inhibit the growth of gram-negative bacteria by increasing membrane permeability. J. Clin. Invest. 111, 1589–1602 (2003).
Larsen, J. M. et al. Divergent pro-inflammatory profile of human dendritic cells in response to commensal and pathogenic bacteria associated with the airway microbiota. PLoS ONE 7, e31976 (2012).
van den Bogert, B., Meijerink, M., Zoetendal, E. G., Wells, J. M. & Kleerebezem, M. Immunomodulatory properties of streptococcus and veillonella isolates from the human small intestine microbiota. PLoS ONE 9, e114277 (2014).
Trompette, A. et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat. Med. 20, 159–166 (2014).
Thorburn, A. N. et al. Evidence that asthma is a developmental origin disease influenced by maternal diet and bacterial metabolites. Nat. Commun. 6, 7320 (2015).
Tan, L., Wang, H., Li, C. & Pan, Y. 16s rdna-based metagenomic analysis of dental plaque and lung bacteria in patients with severe acute exacerbations of chronic obstructive pulmonary disease. J. Periodontal Res. 49, 760–769 (2014).
To, K. K. et al. Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by sars-cov-2: an observational cohort study. Lancet Infect. Dis. 20, 565–574 (2020).
Mammen, M. J., Scannapieco, F. A. & Sethi, S. Oral-lung microbiome interactions in lung diseases. Periodontol 2000 83, 234–241 (2020).
Muhlebach, M. S. et al. Anaerobic bacteria cultured from cystic fibrosis airways correlate to milder disease: a multisite study. Eur. Respir. J. 52, 1800242 (2018).
Yan, X. et al. Discovery and validation of potential bacterial biomarkers for lung cancer. Am. J. Cancer Res. 5, 3111–3122 (2015).
Duytschaever, G. et al. Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Appl Environ. Microbiol. 77, 8015–8024 (2011).
Zhernakova, A. et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. Science 352, 565–569 (2016).
Qin, J. et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464, 59–65 (2010).
Ormerod, K. L. et al. Genomic characterization of the uncultured bacteroidales family s24-7 inhabiting the guts of homeothermic animals. Microbiome 4, 36 (2016).
Budden, K. F. et al. Emerging pathogenic links between microbiota and the gut-lung axis. Nat. Rev. Microbiol. 15, 55–63 (2017).
Chung, K. F. Airway microbial dysbiosis in asthmatic patients: a target for prevention and treatment? J. Allergy Clin. Immunol. 139, 1071–1081 (2017).
Hewitt, R. J. & Lloyd, C. M. Regulation of immune responses by the airway epithelial cell landscape. Nat. Rev. Immunol. 21, 347–362 (2021).
Mazmanian, S. K., Round, J. L. & Kasper, D. L. A microbial symbiosis factor prevents intestinal inflammatory disease. Nature 453, 620–625 (2008).
Depner, M. et al. Maturation of the gut microbiome during the first year of life contributes to the protective farm effect on childhood asthma. Nat. Med. 26, 1766–1775 (2020).
Tang, J., Xu, L., Zeng, Y. & Gong, F. Effect of gut microbiota on lps-induced acute lung injury by regulating the tlr4/nf-kb signaling pathway. Int. Immunopharmacol. 91, 107272 (2021).
Gauguet, S. et al. Intestinal microbiota of mice influences resistance to staphylococcus aureus pneumonia. Infect. Immun. 83, 4003–4014 (2015).
Jeyanathan, M. et al. Parenteral bcg vaccine induces lung-resident memory macrophages and trained immunity via the gut-lung axis. Nat. Immunol. 23, 1687–1702 (2022).
Ghorbani, P. et al. Short-chain fatty acids affect cystic fibrosis airway inflammation and bacterial growth. Eur. Respir. J. 46, 1033–1045 (2015).
Blacher, E., Levy, M., Tatirovsky, E. & Elinav, E. Microbiome-modulated metabolites at the interface of host immunity. J. Immunol. 198, 572–580 (2017).
Schulthess, J. et al. The short chain fatty acid butyrate imprints an antimicrobial program in macrophages. Immunity 50, 432–445.e437 (2019).
Mirkovic, B. et al. The role of short-chain fatty acids, produced by anaerobic bacteria, in the cystic fibrosis airway. Am. J. Respir. Crit. Care Med. 192, 1314–1324 (2015).
Evans, C. R. et al. Untargeted lc-ms metabolomics of bronchoalveolar lavage fluid differentiates acute respiratory distress syndrome from health. J. Proteome Res. 13, 640–649 (2014).
Zhou, X. & Liao, Y. Gut-lung crosstalk in sepsis-induced acute lung injury. Front. Microbiol. 12, 779620 (2021).
Southam, D. S., Dolovich, M., O’Byrne, P. M. & Inman, M. D. Distribution of intranasal instillations in mice: effects of volume, time, body position, and anesthesia. Am. J. Physiol. Lung Cell Mol. Physiol. 282, L833–L839 (2002).
Yildiz, S., Mazel-Sanchez, B., Kandasamy, M., Manicassamy, B. & Schmolke, M. Influenza a virus infection impacts systemic microbiota dynamics and causes quantitative enteric dysbiosis. Microbiome 6, 9 (2018).
Deriu, E. et al. Influenza virus affects intestinal microbiota and secondary salmonella infection in the gut through type i interferons. PLoS Pathog. 12, e1005572 (2016).
Roussos, A., Koursarakos, P., Patsopoulos, D., Gerogianni, I. & Philippou, N. Increased prevalence of irritable bowel syndrome in patients with bronchial asthma. Respir. Med. 97, 75–79 (2003).
Rutten, E. P. A., Lenaerts, K., Buurman, W. A. & Wouters, E. F. M. Disturbed intestinal integrity in patients with copd: effects of activities of daily living. Chest 145, 245–252 (2014).
Yazar, A. et al. Respiratory symptoms and pulmonary functional changes in patients with irritable bowel syndrome. Am. J. Gastroenterol. 96, 1511–1516 (2001).
Vieira, W. A. & Pretorius, E. The impact of asthma on the gastrointestinal tract (git). J. Asthma Allergy 3, 123–130 (2010).
Butler, M. I., Cryan, J. F. & Dinan, T. G. Man and the microbiome: a new theory of everything? Annu. Rev. Clin. Psychol. 15, 371–398 (2019).
Hosang, L. et al. The lung microbiome regulates brain autoimmunity. Nature 603, 138–144 (2022).
Martens, E. C., Neumann, M. & Desai, M. S. Interactions of commensal and pathogenic microorganisms with the intestinal mucosal barrier. Nat. Rev. Microbiol. 16, 457–470 (2018).
Marsland, B. J., Trompette, A. & Gollwitzer, E. S. The gut-lung axis in respiratory disease. Ann. Am. Thorac. Soc. 12, S150–S156 (2015).
Beutler, B. Innate immunity: an overview. Mol. Immunol. 40, 845–859 (2004).
Rakoff-Nahoum, S., Paglino, J., Eslami-Varzaneh, F., Edberg, S. & Medzhitov, R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell 118, 229–241 (2004).
Henao-Mejia, J., Elinav, E., Thaiss, C. A. & Flavell, R. A. Inflammasomes and metabolic disease. Annu. Rev. Physiol. 76, 57–78 (2014).
Aagaard, K. et al. The placenta harbors a unique microbiome. Sci. Transl. Med. 6, 237ra265 (2014).
Gomez de Aguero, M. et al. The maternal microbiota drives early postnatal innate immune development. Science 351, 1296–1302 (2016).
Payne, M. S. et al. Molecular microbiological characterization of preterm neonates at risk of bronchopulmonary dysplasia. Pediatr. Res. 67, 412–418 (2010).
Stressmann, F. A. et al. The use of culture-independent tools to characterize bacteria in endo-tracheal aspirates from pre-term infants at risk of bronchopulmonary dysplasia. J. Perinat. Med. 38, 333–337 (2010).
Mourani, P. M., Harris, J. K., Sontag, M. K., Robertson, C. E. & Abman, S. H. Molecular identification of bacteria in tracheal aspirate fluid from mechanically ventilated preterm infants. PLoS ONE 6, e25959 (2011).
Lohmann, P. et al. The airway microbiome of intubated premature infants: characteristics and changes that predict the development of bronchopulmonary dysplasia. Pediatr. Res. 76, 294–301 (2014).
Lauder, A. P. et al. Comparison of placenta samples with contamination controls does not provide evidence for a distinct placenta microbiota. Microbiome 4, 29 (2016).
Yatsunenko, T. et al. Human gut microbiome viewed across age and geography. Nature 486, 222–227 (2012).
Biesbroek, G. et al. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. Am. J. Respir. Crit. Care Med. 190, 1283–1292 (2014).
Mika, M. et al. Dynamics of the nasal microbiota in infancy: a prospective cohort study. J. Allergy Clin. Immunol. 135, 905–912.e911 (2015).
Vissing, N. H., Chawes, B. L. & Bisgaard, H. Increased risk of pneumonia and bronchiolitis after bacterial colonization of the airways as neonates. Am. J. Respir. Crit. Care Med. 188, 1246–1252 (2013).
Thaiss, C. A., Levy, M., Suez, J. & Elinav, E. The interplay between the innate immune system and the microbiota. Curr. Opin. Immunol. 26, 41–48 (2014).
Hu, X. et al. Single-cell transcriptomics reveals distinct cell response between acute and chronic pulmonary infection of pseudomonas aeruginosa. MedComm (2020) 3, e193 (2022).
Khosravi, A. et al. Gut microbiota promote hematopoiesis to control bacterial infection. Cell Host Microbe 15, 374–381 (2014).
Hill, D. A. et al. Commensal bacteria-derived signals regulate basophil hematopoiesis and allergic inflammation. Nat. Med. 18, 538–546 (2012).
Kim, Y. G. et al. Gut dysbiosis promotes m2 macrophage polarization and allergic airway inflammation via fungi-induced pge(2). Cell Host Microbe 15, 95–102 (2014).
Olszak, T. et al. Microbial exposure during early life has persistent effects on natural killer t cell function. Science 336, 489–493 (2012).
Clarke, T. B. Early innate immunity to bacterial infection in the lung is regulated systemically by the commensal microbiota via nod-like receptor ligands. Infect. Immun. 82, 4596–4606 (2014).
Brown, R. L., Sequeira, R. P. & Clarke, T. B. The microbiota protects against respiratory infection via gm-csf signaling. Nat. Commun. 8, 1512 (2017).
Uehara, A., Fujimoto, Y., Fukase, K. & Takada, H. Various human epithelial cells express functional toll-like receptors, nod1 and nod2 to produce anti-microbial peptides, but not proinflammatory cytokines. Mol. Immunol. 44, 3100–3111 (2007).
Kim, D. Y. et al. The airway antigen sampling system: Respiratory m cells as an alternative gateway for inhaled antigens. J. Immunol. 186, 4253–4262 (2011).
Jahnsen, F. L. et al. Accelerated antigen sampling and transport by airway mucosal dendritic cells following inhalation of a bacterial stimulus. J. Immunol. 177, 5861–5867 (2006).
Gollwitzer, E. S. et al. Lung microbiota promotes tolerance to allergens in neonates via pd-l1. Nat. Med. 20, 642–647 (2014).
Iwasaki, A. & Medzhitov, R. Control of adaptive immunity by the innate immune system. Nat. Immunol. 16, 343–353 (2015).
Beauruelle, C., Guilloux, C. A., Lamoureux, C. & Hery-Arnaud, G. The human microbiome, an emerging key player in the sex gap in respiratory diseases. Front. Med. 8, 600879 (2021).
Le Noci, V. et al. Modulation of pulmonary microbiota by antibiotic or probiotic aerosol therapy: a strategy to promote immunosurveillance against lung metastases. Cell Rep. 24, 3528–3538 (2018).
Youn, H. N. et al. Intranasal administration of live lactobacillus species facilitates protection against influenza virus infection in mice. Antivir. Res. 93, 138–143 (2012).
Levy, M., Thaiss, C. A. & Elinav, E. Metagenomic cross-talk: The regulatory interplay between immunogenomics and the microbiome. Genome Med. 7, 120 (2015).
Ramanan, D., Tang, M. S., Bowcutt, R., Loke, P. & Cadwell, K. Bacterial sensor nod2 prevents inflammation of the small intestine by restricting the expansion of the commensal bacteroides vulgatus. Immunity 41, 311–324 (2014).
Elinav, E. et al. Nlrp6 inflammasome regulates colonic microbial ecology and risk for colitis. Cell 145, 745–757 (2011).
Vijay-Kumar, M. et al. Metabolic syndrome and altered gut microbiota in mice lacking toll-like receptor 5. Science 328, 228–231 (2010).
Tian, Z. et al. Dynamic alterations in the lung microbiota in a rat model of lipopolysaccharide-induced acute lung injury. Sci. Rep. 12, 4791 (2022).
Evans, S. E., Xu, Y., Tuvim, M. J. & Dickey, B. F. Inducible innate resistance of lung epithelium to infection. Annu. Rev. Physiol. 72, 413–435 (2010).
Leiva-Juarez, M. M., Kolls, J. K. & Evans, S. E. Lung epithelial cells: therapeutically inducible effectors of antimicrobial defense. Mucosal Immunol. 11, 21–34 (2018).
Invernizzi, R., Lloyd, C. M. & Molyneaux, P. L. Respiratory microbiome and epithelial interactions shape immunity in the lungs. Immunology 160, 171–182 (2020).
Bonilla, F. A. & Oettgen, H. C. Adaptive immunity. J. Allergy Clin. Immunol. 125, S33–S40 (2010).
Naik, S. et al. Commensal-dendritic-cell interaction specifies a unique protective skin immune signature. Nature 520, 104–108 (2015).
Yasutomi, Y. et al. Activated mucosal-associated invariant t cells have a pathogenic role in a murine model of inflammatory bowel disease. Cell Mol. Gastroenterol. Hepatol. 13, 81–93 (2022).
Koch, M. A. et al. Maternal igg and iga antibodies dampen mucosal t helper cell responses in early life. Cell 165, 827–841 (2016).
Wu, B. G. et al. Episodic aspiration with oral commensals induces a myd88-dependent, pulmonary t-helper cell type 17 response that mitigates susceptibility to streptococcus pneumoniae. Am. J. Respir. Crit. Care Med. 203, 1099–1111 (2021).
Remot, A. et al. Bacteria isolated from lung modulate asthma susceptibility in mice. ISME J. 11, 1061–1074 (2017).
Segal, L. N. et al. Anaerobic bacterial fermentation products increase tuberculosis risk in antiretroviral-drug-treated hiv patients. Cell Host Microbe 21, 530–537.e534 (2017).
Romani, L. et al. Microbiota control of a tryptophan-ahr pathway in disease tolerance to fungi. Eur. J. Immunol. 44, 3192–3200 (2014).
Robinson, K. M. et al. Influenza a virus exacerbates staphylococcus aureus pneumonia in mice by attenuating antimicrobial peptide production. J. Infect. Dis. 209, 865–875 (2014).
Kim, E. Y. et al. Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat. Med. 14, 633–640 (2008).
Krishnamoorthy, N. et al. Early infection with respiratory syncytial virus impairs regulatory t cell function and increases susceptibility to allergic asthma. Nat. Med. 18, 1525–1530 (2012).
Sims, T. T. et al. Gut microbiome diversity is an independent predictor of survival in cervical cancer patients receiving chemoradiation. Commun. Biol. 4, 237 (2021).
Jin, C. et al. Commensal microbiota promote lung cancer development via gammadelta t cells. Cell 176, 998–1013.e1016 (2019).
Twigg, H. L. 3rd et al. Effect of advanced hiv infection on the respiratory microbiome. Am. J. Respir. Crit. Care Med. 194, 226–235 (2016).
Iwai, S. et al. The lung microbiome of ugandan hiv-infected pneumonia patients is compositionally and functionally distinct from that of san franciscan patients. PLoS ONE 9, e95726 (2014).
Lozupone, C. et al. Widespread colonization of the lung by tropheryma whipplei in hiv infection. Am. J. Respir. Crit. Care Med. 187, 1110–1117 (2013).
Dickson, R. P., Erb-Downward, J. R. & Huffnagle, G. B. The role of the bacterial microbiome in lung disease. Expert Rev. Respir. Med. 7, 245–257 (2013).
Garcia-Nunez, M. et al. Severity-related changes of bronchial microbiome in chronic obstructive pulmonary disease. J. Clin. Microbiol. 52, 4217–4223 (2014).
Tsay, J. J. et al. Airway microbiota is associated with upregulation of the pi3k pathway in lung cancer. Am. J. Respir. Crit. Care Med. 198, 1188–1198 (2018).
Gustafson, A. M. et al. Airway pi3k pathway activation is an early and reversible event in lung cancer development. Sci. Transl. Med. 2, 26ra25 (2010).
Jackson, D. J. & Johnston, S. L. The role of viruses in acute exacerbations of asthma. J. Allergy Clin. Immunol. 125, 1178–1187 (2010). quiz 1188-1179.
Hansbro, P. M. et al. Mechanisms and treatments for severe, steroid-resistant allergic airway disease and asthma. Immunol. Rev. 278, 41–62 (2017).
Pijnenburg, M. W., Frey, U., De Jongste, J. C. & Saglani, S. Childhood asthma: pathogenesis and phenotypes. Eur. Respir. J. 59, 2100731 (2022).
Cardenas, P. A. et al. Upper airways microbiota in antibiotic-naive wheezing and healthy infants from the tropics of rural ecuador. PLoS ONE 7, e46803 (2012).
Huang, Y. J. et al. The microbiome in allergic disease: current understanding and future opportunities-2017 practall document of the american academy of allergy, asthma & immunology and the european academy of allergy and clinical immunology. J. Allergy Clin. Immunol. 139, 1099–1110 (2017).
Larsen, J. M. The immune response to prevotella bacteria in chronic inflammatory disease. Immunology 151, 363–374 (2017).
Lyon, J. The lung microbiome: key to respiratory ills? JAMA 317, 1713–1714 (2017).
Durack, J. et al. Features of the bronchial bacterial microbiome associated with atopy, asthma, and responsiveness to inhaled corticosteroid treatment. J. Allergy Clin. Immunol. 140, 63–75 (2017).
Essilfie, A. T. et al. Combined haemophilus influenzae respiratory infection and allergic airways disease drives chronic infection and features of neutrophilic asthma. Thorax 67, 588–599 (2012).
Kim, R. Y. et al. Role for nlrp3 inflammasome-mediated, il-1beta-dependent responses in severe, steroid-resistant asthma. Am. J. Respir. Crit. Care Med. 196, 283–297 (2017).
Goleva, E. et al. The effects of airway microbiome on corticosteroid responsiveness in asthma. Am. J. Respir. Crit. Care Med. 188, 1193–1201 (2013).
Rabe, K. F. & Watz, H. Chronic obstructive pulmonary disease. Lancet 389, 1931–1940 (2017).
Labaki, W. W. & Rosenberg, S. R. Chronic obstructive pulmonary disease. Ann. Intern. Med. 173, ITC17–ITC32 (2020).
Sze, M. A. et al. The lung tissue microbiome in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 185, 1073–1080 (2012).
Sze, M. A. et al. Host response to the lung microbiome in chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 192, 438–445 (2015).
Yan, Z. et al. Multi-omics analyses of airway host-microbe interactions in chronic obstructive pulmonary disease identify potential therapeutic interventions. Nat. Microbiol. 7, 1361–1375 (2022).
Feigelman, R. et al. Sputum DNA sequencing in cystic fibrosis: Non-invasive access to the lung microbiome and to pathogen details. Microbiome 5, 20 (2017).
Madapoosi, S. S. et al. Lung microbiota and metabolites collectively associate with clinical outcomes in milder stage chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 206, 427–439 (2022).
Everaerts, S. et al. Sensitization to aspergillus fumigatus as a risk factor for bronchiectasis in copd. Int J. Chron. Obstruct. Pulmon. Dis. 12, 2629–2638 (2017).
Goss, C. H. & Burns, J. L. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 62, 360–367 (2007).
Lipuma, J. J. The changing microbial epidemiology in cystic fibrosis. Clin. Microbiol. Rev. 23, 299–323 (2010).
Cox, M. J. et al. Longitudinal assessment of sputum microbiome by sequencing of the 16s rrna gene in non-cystic fibrosis bronchiectasis patients. PLoS ONE 12, e0170622 (2017).
Malhotra, S., Limoli, D. H., English, A. E., Parsek, M. R. & Wozniak, D. J. Mixed communities of mucoid and nonmucoid pseudomonas aeruginosa exhibit enhanced resistance to host antimicrobials. mBio 9, e00275–18 (2018).
Carmody, L. A. et al. The daily dynamics of cystic fibrosis airway microbiota during clinical stability and at exacerbation. Microbiome 3, 12 (2015).
Flynn, J. M., Niccum, D., Dunitz, J. M. & Hunter, R. C. Evidence and role for bacterial mucin degradation in cystic fibrosis airway disease. PLoS Pathog. 12, e1005846 (2016).
Blanchard, A. C. & Waters, V. J. Opportunistic pathogens in cystic fibrosis: epidemiology and pathogenesis of lung infection. J. Pediatr. Infect. Dis. Soc. 11, S3–S12 (2022).
Lindgren, N. R., McDaniel, M. S., Novak, L. & Swords, W. E. Acute polymicrobial airway infections: Analysis in cystic fibrosis mice. Microbiology (Reading) 169, 001290 (2023).
Bertelsen, A., Elborn, J. S. & Schock, B. C. Microbial interaction: prevotella spp. Reduce p. Aeruginosa induced inflammation in cystic fibrosis bronchial epithelial cells. J. Cyst. Fibros. 20, 682–691 (2021).
Boutin, S. et al. Chronic but not intermittent infection with pseudomonas aeruginosa is associated with global changes of the lung microbiome in cystic fibrosis. Eur. Respir. J. 50, 1701086 (2017).
Cuthbertson, L. et al. Lung function and microbiota diversity in cystic fibrosis. Microbiome 8, 45 (2020).
Chotirmall, S. H. et al. Sputum candida albicans presages fev(1) decline and hospital-treated exacerbations in cystic fibrosis. Chest 138, 1186–1195 (2010).
Abdillah, A. & Ranque, S. Chronic diseases associated with malassezia yeast. J. Fungi 7, 855 (2021).
Amin, R., Dupuis, A., Aaron, S. D. & Ratjen, F. The effect of chronic infection with aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 137, 171–176 (2010).
Molyneaux, P. L. et al. Outgrowth of the bacterial airway microbiome after rhinovirus exacerbation of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 188, 1224–1231 (2013).
Richeldi, L., Collard, H. R. & Jones, M. G. Idiopathic pulmonary fibrosis. Lancet 389, 1941–1952 (2017).
Han, M. K. et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the comet study. Lancet Respir. Med. 2, 548–556 (2014).
Molyneaux, P. L. et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 190, 906–913 (2014).
Invernizzi, R. et al. The respiratory microbiome in chronic hypersensitivity pneumonitis is distinct from that of idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 203, 339–347 (2021).
D’Alessandro-Gabazza, C. N. et al. A staphylococcus pro-apoptotic peptide induces acute exacerbation of pulmonary fibrosis. Nat. Commun. 11, 1539 (2020).
Yang, D. et al. Dysregulated lung commensal bacteria drive interleukin-17b production to promote pulmonary fibrosis through their outer membrane vesicles. Immunity 50, 692–706.e697 (2019).
Molyneaux, P. L. et al. Host-microbial interactions in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 195, 1640–1650 (2017).
O’Dwyer, D. N. et al. The peripheral blood proteome signature of idiopathic pulmonary fibrosis is distinct from normal and is associated with novel immunological processes. Sci. Rep. 7, 46560 (2017).
Celada, L. J. et al. Pd-1 up-regulation on cd4(+) t cells promotes pulmonary fibrosis through stat3-mediated il-17a and tgf-beta1 production. Sci. Transl. Med. 10, eaar8356 (2018).
Rao, L. Z. et al. Il-24 deficiency protects mice against bleomycin-induced pulmonary fibrosis by repressing il-4-induced m2 program in macrophages. Cell Death Differ. 28, 1270–1283 (2021).
Molyneaux, P. L. et al. Changes in the respiratory microbiome during acute exacerbations of idiopathic pulmonary fibrosis. Respir. Res. 18, 29 (2017).
Ramaswamy, A. et al. Immune dysregulation and autoreactivity correlate with disease severity in sars-cov-2-associated multisystem inflammatory syndrome in children. Immunity 54, 1083–1095.e1087 (2021).
Taille, C. et al. Identification of periplakin as a new target for autoreactivity in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 183, 759–766 (2011).
Chalmers, J. D. et al. Neutrophil elastase activity is associated with exacerbations and lung function decline in bronchiectasis. Am. J. Respir. Crit. Care Med. 195, 1384–1393 (2017).
Lee, S. H. et al. Characterization of microbiota in bronchiectasis patients with different disease severities. J. Clin. Med. 7, 429 (2018).
Taylor, S. L. et al. Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann. Am. Thorac. Soc. 12, 701–707 (2015).
Ubags, N. D. J. & Marsland, B. J. Mechanistic insight into the function of the microbiome in lung diseases. Eur. Respir. J. 50, 1602467 (2017).
Tunney, M. M. et al. Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am. J. Respir. Crit. Care Med. 187, 1118–1126 (2013).
Dicker, A. J. et al. The sputum microbiome and clinical outcomes in patients with bronchiectasis: a prospective observational study. Lancet Respir. Med. 9, 885–896 (2021).
Rogers, G. B., Bruce, K. D., Martin, M. L., Burr, L. D. & Serisier, D. J. The effect of long-term macrolide treatment on respiratory microbiota composition in non-cystic fibrosis bronchiectasis: an analysis from the randomised, double-blind, placebo-controlled bless trial. Lancet Respir. Med. 2, 988–996 (2014).
Loebinger, M. R. et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur. Respir. J. 34, 843–849 (2009).
Finch, S., McDonnell, M. J., Abo-Leyah, H., Aliberti, S. & Chalmers, J. D. A comprehensive analysis of the impact of pseudomonas aeruginosa colonization on prognosis in adult bronchiectasis. Ann. Am. Thorac. Soc. 12, 1602–1611 (2015).
Chalmers, J. D. et al. The bronchiectasis severity index. An international derivation and validation study. Am. J. Respir. Crit. Care Med. 189, 576–585 (2014).
Martinez-Garcia, M. A. et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the faced score. Eur. Respir. J. 43, 1357–1367 (2014).
Mac Aogain, M. et al. Immunological corollary of the pulmonary mycobiome in bronchiectasis: the CAMEB study. Eur. Respir. J. 52, 1800766 (2018).
Kapur, N., Mackay, I. M., Sloots, T. P., Masters, I. B. & Chang, A. B. Respiratory viruses in exacerbations of non-cystic fibrosis bronchiectasis in children. Arch. Dis. Child 99, 749–753 (2014).
Gao, Y. H. et al. The role of viral infection in pulmonary exacerbations of bronchiectasis in adults: a prospective study. Chest 147, 1635–1643 (2015).
Boyton, R. J. & Altmann, D. M. Immune regulation in idiopathic bronchiectasis. Ann. N. Y. Acad. Sci. 1272, 68–72 (2012).
Pasteur, M. C. et al. An investigation into causative factors in patients with bronchiectasis. Am. J. Respir. Crit. Care Med. 162, 1277–1284 (2000).
Wynn-Williams, N. Bronchiectasis: a study centred on bedford and its environs. Br. Med. J. 1, 1194–1199 (1953).
Guan, W. J., Han, X. R., de la Rosa-Carrillo, D. & Martinez-Garcia, M. A. The significant global economic burden of bronchiectasis: a pending matter. Eur. Respir. J. 53, 1802392 (2019).
Li, L. et al. Neisseria species as pathobionts in bronchiectasis. Cell Host Microbe 30, 1311–1327.e1318 (2022).
Gramegna, A. et al. Neutrophil elastase in bronchiectasis. Respir. Res. 18, 211 (2017).
Oriano, M. et al. Sputum neutrophil elastase associates with microbiota and pseudomonas aeruginosa in bronchiectasis. Eur. Respir. J. 56, 2000769 (2020).
Rigauts, C. et al. R othia mucilaginosa is an anti-inflammatory bacterium in the respiratory tract of patients with chronic lung disease. Eur. Respir. J. 59, 2101293 (2022).
Iwai, S. et al. Oral and airway microbiota in hiv-infected pneumonia patients. J. Clin. Microbiol. 50, 2995–3002 (2012).
Shenoy, M. K. et al. Immune response and mortality risk relate to distinct lung microbiomes in patients with hiv and pneumonia. Am. J. Respir. Crit. Care Med. 195, 104–114 (2017).
Emonet, S. et al. Identification of respiratory microbiota markers in ventilator-associated pneumonia. Intensive Care Med. 45, 1082–1092 (2019).
Woo, S. et al. The dynamics of respiratory microbiota during mechanical ventilation in patients with pneumonia. J. Clin. Med. 9, 638 (2020).
Vazquez-Perez, J. A. et al. Alveolar microbiota profile in patients with human pulmonary tuberculosis and interstitial pneumonia. Micro. Pathog. 139, 103851 (2020).
Shankar, J. et al. Looking beyond respiratory cultures: Microbiome-cytokine signatures of bacterial pneumonia and tracheobronchitis in lung transplant recipients. Am. J. Transpl. 16, 1766–1778 (2016).
Poroyko, V. et al. Alterations of lung microbiota in a mouse model of lps-induced lung injury. Am. J. Physiol. Lung Cell Mol. Physiol. 309, L76–L83 (2015).
Flume, P. A. et al. Cystic fibrosis pulmonary guidelines: treatment of pulmonary exacerbations. Am. J. Respir. Crit. Care Med.180, 802–808 (2009).
Sethi, S., Evans, N., Grant, B. J. & Murphy, T. F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. N. Engl. J. Med. 347, 465–471 (2002).
Herzig, S. J., Howell, M. D., Ngo, L. H. & Marcantonio, E. R. Acid-suppressive medication use and the risk for hospital-acquired pneumonia. JAMA 301, 2120–2128 (2009).
Siempos, I. I., Ntaidou, T. K. & Falagas, M. E. Impact of the administration of probiotics on the incidence of ventilator-associated pneumonia: a meta-analysis of randomized controlled trials. Crit. Care Med. 38, 954–962 (2010).
Flierl, M. A. et al. Phagocyte-derived catecholamines enhance acute inflammatory injury. Nature 449, 721–725 (2007).
Freestone, P. Communication between bacteria and their hosts. Science 2013, 361073 (2013).
Freestone, P. P. et al. Pseudomonas aeruginosa-catecholamine inotrope interactions: a contributory factor in the development of ventilator-associated pneumonia? Chest 142, 1200–1210 (2012).
Xavier-Santos, D. et al. Evidences and perspectives of the use of probiotics, prebiotics, synbiotics, and postbiotics as adjuvants for prevention and treatment of covid-19: a bibliometric analysis and systematic review. Trends Food Sci. Technol. 120, 174–192 (2022).
Kitsios, G. D. et al. Respiratory tract dysbiosis is associated with worse outcomes in mechanically ventilated patients. Am. J. Respir. Crit. Care Med. 202, 1666–1677 (2020).
Kyo, M. et al. Unique patterns of lower respiratory tract microbiota are associated with inflammation and hospital mortality in acute respiratory distress syndrome. Respir. Res. 20, 246 (2019).
Peukert, K. et al. Inhibition of caspase-1 with tetracycline ameliorates acute lung injury. Am. J. Respir. Crit. Care Med. 204, 53–63 (2021).
Ashley, S. L. et al. Lung and gut microbiota are altered by hyperoxia and contribute to oxygen-induced lung injury in mice. Sci. Transl. Med. 12, eaau9959 (2020).
Meduri, G. U. et al. Inflammatory cytokines in the bal of patients with ards. Persistent elevation over time predicts poor outcome. Chest 108, 1303–1314 (1995).
Liao, M. et al. Single-cell landscape of bronchoalveolar immune cells in patients with covid-19. Nat. Med. 26, 842–844 (2020).
Merenstein, C. et al. Signatures of covid-19 severity and immune response in the respiratory tract microbiome. mBio 12, e0177721 (2021).
Dong, Q., Chen, E. S., Zhao, C. & Jin, C. Host-microbiome interaction in lung cancer. Front. Immunol. 12, 679829 (2021).
McLean, A. E. B. et al. The emerging role of the lung microbiome and its importance in non-small cell lung cancer diagnosis and treatment. Lung Cancer 165, 124–132 (2022).
Cheng, C. et al. Characterization of the lung microbiome and exploration of potential bacterial biomarkers for lung cancer. Transl. Lung Cancer Res. 9, 693–704 (2020).
Mao, Q. et al. Interplay between the lung microbiome and lung cancer. Cancer Lett. 415, 40–48 (2018).
Vogtmann, E. & Goedert, J. J. Epidemiologic studies of the human microbiome and cancer. Br. J. Cancer 114, 237–242 (2016).
Picardo, S. L., Coburn, B. & Hansen, A. R. The microbiome and cancer for clinicians. Crit. Rev. Oncol. Hematol. 141, 1–12 (2019).
Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2021. CA Cancer J. Clin. 71, 7–33 (2021).
Akinosoglou, K. S., Karkoulias, K. & Marangos, M. Infectious complications in patients with lung cancer. Eur. Rev. Med. Pharm. Sci. 17, 8–18 (2013).
Brenner, D. R. et al. Previous lung diseases and lung cancer risk: A pooled analysis from the international lung cancer consortium. Am. J. Epidemiol. 176, 573–585 (2012).
Akhtar, N. & Bansal, J. G. Risk factors of lung cancer in nonsmoker. Curr. Probl. Cancer 41, 328–339 (2017).
Xu, N. et al. Microbiota dysbiosis in lung cancer: evidence of association and potential mechanisms. Transl. Lung Cancer Res. 9, 1554–1568 (2020).
Weinberg, F., Dickson, R. P., Nagrath, D. & Ramnath, N. The lung microbiome: a central mediator of host inflammation and metabolism in lung cancer patients?. Cancers 13, 13 (2020).
Nagasaka, M. et al. Gut microbiome and response to checkpoint inhibitors in non-small cell lung cancer-a review. Crit. Rev. Oncol. Hematol. 145, 102841 (2020).
Khan, F. H. et al. Microbiome dysbiosis and epigenetic modulations in lung cancer: from pathogenesis to therapy. Semin. Cancer Biol. 86, 732–742 (2022).
Goto, T. Microbiota and lung cancer. Semin. Cancer Biol. 86, 1–10 (2022).
Kovaleva, O. V. et al. Human lung microbiome on the way to cancer. J. Immunol. Res. 2019, 1394191 (2019).
Nesic, D., Hsu, Y. & Stebbins, C. E. Assembly and function of a bacterial genotoxin. Nature 429, 429–433 (2004).
Cuevas-Ramos, G. et al. Escherichia coli induces DNA damage in vivo and triggers genomic instability in mammalian cells. Proc. Natl Acad. Sci. USA 107, 11537–11542 (2010).
Zhai, T., Li, S., Hu, W., Li, D. & Leng, S. Potential micronutrients and phytochemicals against the pathogenesis of chronic obstructive pulmonary disease and lung cancer. Nutrients 10, 813 (2018).
Tsay, J. J. et al. Lower airway dysbiosis affects lung cancer progression. Cancer Discov. 11, 293–307 (2021).
Parris, B. A., O’Farrell, H. E., Fong, K. M. & Yang, I. A. Chronic obstructive pulmonary disease (copd) and lung cancer: Common pathways for pathogenesis. J. Thorac. Dis. 11, S2155–S2172 (2019).
Pilaniya, V., Gera, K., Kunal, S. & Shah, A. Pulmonary tuberculosis masquerading as metastatic lung disease. Eur. Respir. Rev. 25, 97–98 (2016).
Liang, H. Y. et al. Facts and fiction of the relationship between preexisting tuberculosis and lung cancer risk: a systematic review. Int. J. Cancer 125, 2936–2944 (2009).
Rodescu, D., Abeles, H., Zelefsky, M. N. & Williams, M. H. Jr. Accelerated growth of lung cancer in association with rifampicin administration for tuberculosis. Lancet 2, 983 (1981).
Huang, D. et al. The characterization of lung microbiome in lung cancer patients with different clinicopathology. Am. J. Cancer Res. 9, 2047–2063 (2019).
Kim, O. H. et al. The microbiome of lung cancer tissue and its association with pathological and clinical parameters. Am. J. Cancer Res. 12, 2350–2362 (2022).
Apopa, P. L. et al. Parp1 is up-regulated in non-small cell lung cancer tissues in the presence of the cyanobacterial toxin microcystin. Front. Microbiol. 9, 1757 (2018).
Patnaik, S. K. et al. Lower airway bacterial microbiome may influence recurrence after resection of early-stage non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 161, 419–429.e416 (2021).
Najafi, S. et al. The composition of lung microbiome in lung cancer: a systematic review and meta-analysis. BMC Microbiol. 21, 315 (2021).
Zheng, L. et al. Lung microbiome alterations in nsclc patients. Sci. Rep. 11, 11736 (2021).
Peters, B. A. et al. The microbiome in lung cancer tissue and recurrence-free survival. Cancer Epidemiol. Biomark. Prev. 28, 731–740 (2019).
Yagi, K., Huffnagle, G. B., Lukacs, N. W. & Asai, N. The lung microbiome during health and disease. Int. J. Mol. Sci. 22, 10872 (2021).
Masuhiro, K. et al. Bronchoalveolar lavage fluid reveals factors contributing to the efficacy of pd-1 blockade in lung cancer. JCI Insight 7, e157915 (2022).
Newsome, R. C. et al. Interaction of bacterial genera associated with therapeutic response to immune checkpoint pd-1 blockade in a united states cohort. Genome Med. 14, 35 (2022).
Jang, H. J. et al. Relationship of the lung microbiome with pd-l1 expression and immunotherapy response in lung cancer. Respir. Res. 22, 322 (2021).
Chu, S. et al. Airway fusobacterium is associated with poor response to immunotherapy in lung cancer. Onco Targets Ther. 15, 201–213 (2022).
Kovaleva, O. et al. Lung microbiome differentially impacts survival of patients with non-small cell lung cancer depending on tumor stroma phenotype. Biomedicines 8, 349 (2020).
Liu, Y. et al. Lung tissue microbial profile in lung cancer is distinct from emphysema. Am. J. Cancer Res. 8, 1775–1787 (2018).
Martins, D., Mendes, F. & Schmitt, F. Microbiome: a supportive or a leading actor in lung cancer? Pathobiology 88, 198–207 (2021).
Marshall, E. A. et al. Distinct bronchial microbiome precedes clinical diagnosis of lung cancer. Mol. Cancer 21, 68 (2022).
Li, X. & Saxena, D. The tumor mycobiome: a paradigm shift in cancer pathogenesis. Cell 185, 3648–3651 (2022).
Liu, N. N. et al. The intratumor mycobiome promotes lung cancer progression via myeloid-derived suppressor cells. Cancer Cell 41, 1927–1944.e9 (2023).
Narunsky-Haziza, L. et al. Pan-cancer analyses reveal cancer-type-specific fungal ecologies and bacteriome interactions. Cell 185, 3789–3806.e3717 (2022).
Wostmann, B. S. The germfree animal in nutritional studies. Annu Rev. Nutr. 1, 257–279 (1981).
Yang, Y. S. H., Chou, H. C., Liu, Y. R. & Chen, C. M. Uteroplacental insufficiency causes microbiota disruption and lung development impairment in growth-restricted newborn rats. Nutrients 14, 4388 (2022).
Wang, D. et al. The role of respiratory microbiota in lung cancer. Int J. Biol. Sci. 17, 3646–3658 (2021).
Simonneau, G. et al. Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur. Respir. J. 53, 1801913 (2019).
Zhang, Q. et al. The transient receptor potential vanilloid-3 regulates hypoxia-mediated pulmonary artery smooth muscle cells proliferation via pi3k/akt signaling pathway. Cell Prolif. 51, e12436 (2018).
Shiota, Y. et al. Septic pulmonary embolism associated with periodontal disease: reports of two cases and review of the literature. Chest 121, 652–654 (2002).
Mattar, C. S., Keith, R. L., Byrd, R. P. Jr. & Roy, T. M. Septic pulmonary emboli due to periodontal disease. Respir. Med. 100, 1470–1474 (2006).
Endo, S. et al. Periodontitis-associated septic pulmonary embolism caused by actinomyces species identified by anaerobic culture of bronchoalveolar lavage fluid: a case report. BMC Infect. Dis. 15, 552 (2015).
Wang, W., Li, Y., Han, G., Li, A. & Kong, X. Lactobacillus fermentum cect5716 alleviates the inflammatory response in asthma by regulating tlr2/tlr4 expression. Front. Nutr. 9, 931427 (2022).
Marsh, R. L. et al. Multiple respiratory microbiota profiles are associated with lower airway inflammation in children with protracted bacterial bronchitis. Chest 155, 778–786 (2019).
Wurzel, D. F. et al. Prospective characterization of protracted bacterial bronchitis in children. Chest 145, 1271–1278 (2014).
Marchant, J., Masters, I. B., Champion, A., Petsky, H. & Chang, A. B. Randomised controlled trial of amoxycillin clavulanate in children with chronic wet cough. Thorax 67, 689–693 (2012).
Goyal, V., Grimwood, K., Marchant, J. M., Masters, I. B. & Chang, A. B. Paediatric chronic suppurative lung disease: clinical characteristics and outcomes. Eur. J. Pediatr. 175, 1077–1084 (2016).
Wurzel, D. F. et al. Protracted bacterial bronchitis in children: natural history and risk factors for bronchiectasis. Chest 150, 1101–1108 (2016).
O’Grady, K. F. et al. Upper airway viruses and bacteria and clinical outcomes in children with cough. Pediatr. Pulmonol. 52, 373–381 (2017).
Hare, K. M. et al. Respiratory bacterial pathogens in the nasopharynx and lower airways of australian indigenous children with bronchiectasis. J. Pediatr. 157, 1001–1005 (2010).
Cuthbertson, L. et al. The impact of persistent bacterial bronchitis on the pulmonary microbiome of children. PLoS ONE 12, e0190075 (2017).
Metwally, A. A. et al. Pediatric lung transplantation: dynamics of the microbiome and bronchiolitis obliterans in cystic fibrosis. J. Heart Lung Transpl. 39, 824–834 (2020).
Vos, R. et al. Pseudomonal airway colonisation: Risk factor for bronchiolitis obliterans syndrome after lung transplantation? Eur. Respir. J. 31, 1037–1045 (2008).
Gottlieb, J. et al. Impact of graft colonization with gram-negative bacteria after lung transplantation on the development of bronchiolitis obliterans syndrome in recipients with cystic fibrosis. Respir. Med. 103, 743–749 (2009).
Relman, D. A. The human microbiome: ecosystem resilience and health. Nutr. Rev. 70, S2–S9 (2012).
Schott, C. et al. Bronchiolitis obliterans syndrome susceptibility and the pulmonary microbiome. J. Heart Lung Transpl. 37, 1131–1140 (2018).
Sze, M. A., Utokaparch, S., Elliott, W. M., Hogg, J. C. & Hegele, R. G. Loss of gd1-positive lactobacillus correlates with inflammation in human lungs with copd. BMJ Open 5, e006677 (2015).
Ito, S. et al. Ultra-low dose interleukin-2 promotes immune-modulating function of regulatory t cells and natural killer cells in healthy volunteers. Mol. Ther. 22, 1388–1395 (2014).
Gupta, G. et al. Treatment with ip-10 induces host-protective immune response by regulating the t regulatory cell functioning in leishmania donovani-infected mice. Med. Microbiol. Immunol. 200, 241–253 (2011).
Round, J. L. et al. The toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science 332, 974–977 (2011).
Atarashi, K. et al. Treg induction by a rationally selected mixture of clostridia strains from the human microbiota. Nature 500, 232–236 (2013).
Seve, P. et al. Sarcoidosis: a clinical overview from symptoms to diagnosis. Cells 10, 766 (2021).
Fukui, S. et al. Comparison of lung microbiota between antineutrophil cytoplasmic antibody-associated vasculitis and sarcoidosis. Sci. Rep. 10, 9466 (2020).
Garzoni, C. et al. Microbial communities in the respiratory tract of patients with interstitial lung disease. Thorax 68, 1150–1156 (2013).
Song, Z. et al. Mycobacterial catalase-peroxidase is a tissue antigen and target of the adaptive immune response in systemic sarcoidosis. J. Exp. Med. 201, 755–767 (2005).
Ishige, I., Usui, Y., Takemura, T. & Eishi, Y. Quantitative pcr of mycobacterial and propionibacterial DNA in lymph nodes of japanese patients with sarcoidosis. Lancet 354, 120–123 (1999).
Zimmermann, A. et al. Atopobium and fusobacterium as novel candidates for sarcoidosis-associated microbiota. Eur. Respir. J. 50, 1600746 (2017).
Gupta, S. et al. Comparative analysis of the alveolar microbiome in copd, ecopd, sarcoidosis, and ild patients to identify respiratory illnesses specific microbial signatures. Sci. Rep. 11, 3963 (2021).
Becker, A. et al. The composition of the pulmonary microbiota in sarcoidosis - an observational study. Respir. Res. 20, 46 (2019).
Al-Harbi, A. et al. Lung granuloma: a clinicopathologic study of 158 cases. Ann. Thorac. Med. 12, 278–281 (2017).
Dubaniewicz, A. Mycobacterium tuberculosis heat shock proteins and autoimmunity in sarcoidosis. Autoimmun. Rev. 9, 419–424 (2010).
Dubaniewicz, A. et al. Mycobacterium tuberculosis complex and mycobacterial heat shock proteins in lymph node tissue from patients with pulmonary sarcoidosis. J. Clin. Microbiol. 44, 3448–3451 (2006).
Alam, J., Kim, Y. C. & Choi, Y. Potential role of bacterial infection in autoimmune diseases: a new aspect of molecular mimicry. Immune Netw. 14, 7–13 (2014).
Strauss, J. et al. Invasive potential of gut mucosa-derived fusobacterium nucleatum positively correlates with ibd status of the host. Inflamm. Bowel Dis. 17, 1971–1978 (2011).
Eishi, Y. Etiologic link between sarcoidosis and propionibacterium acnes. Respir. Investig. 51, 56–68 (2013).
Asakawa, N. et al. Immunohistochemical identification of propionibacterium acnes in granuloma and inflammatory cells of myocardial tissues obtained from cardiac sarcoidosis patients. PLoS ONE 12, e0179980 (2017).
Goto, H., Usui, Y., Umazume, A., Uchida, K. & Eishi, Y. Propionibacterium acnes as a possible pathogen of granuloma in patients with ocular sarcoidosis. Br. J. Ophthalmol. 101, 1510–1513 (2017).
Yang, G. et al. Propionibacterium acnes-associated neurosarcoidosis: a case report with review of the literature. Neuropathology 38, 159–164 (2018).
Uchida, K. et al. Propionibacterium acnes-derived circulating immune complexes in sarcoidosis patients. Microorganisms 9, 2194 (2021).
Eishi, Y. et al. Quantitative analysis of mycobacterial and propionibacterial DNA in lymph nodes of japanese and european patients with sarcoidosis. J. Clin. Microbiol. 40, 198–204 (2002).
Zhou, Y. et al. Real-time quantitative reverse transcription-polymerase chain reaction to detect propionibacterial ribosomal rna in the lymph nodes of chinese patients with sarcoidosis. Clin. Exp. Immunol. 181, 511–517 (2015).
Darlington, P. et al. T-cell phenotypes in bronchoalveolar lavage fluid, blood and lymph nodes in pulmonary sarcoidosis–indication for an airborne antigen as the triggering factor in sarcoidosis. J. Intern. Med. 272, 465–471 (2012).
Griffiths, M. J. D. et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir. Res. 6, e000420 (2019).
Chen, H. et al. Inhibition of myeloid differentiation factor 2 by baicalein protects against acute lung injury. Phytomedicine 63, 152997 (2019).
Reiss, L. K., Uhlig, U. & Uhlig, S. Models and mechanisms of acute lung injury caused by direct insults. Eur. J. Cell Biol. 91, 590–601 (2012).
Dickson, R. P. et al. Lung microbiota predict clinical outcomes in critically ill patients. Am. J. Respir. Crit. Care Med. 201, 555–563 (2020).
Schmitt, F. C. F. et al. Pulmonary microbiome patterns correlate with the course of the disease in patients with sepsis-induced ards following major abdominal surgery. J. Hosp. Infect. 105, 438–446 (2020).
Long, M. E., Mallampalli, R. K. & Horowitz, J. C. Pathogenesis of pneumonia and acute lung injury. Clin. Sci. 136, 747–769 (2022).
Matthay, M. A. et al. Alveolar epithelial barrier. Role in lung fluid balance in clinical lung injury. Clin. Chest Med. 21, 477–490 (2000).
Frank, J. A. et al. Physiological and biochemical markers of alveolar epithelial barrier dysfunction in perfused human lungs. Am. J. Physiol. Lung Cell Mol. Physiol. 293, L52–L59 (2007).
Richmond, B. W. et al. Airway bacteria drive a progressive copd-like phenotype in mice with polymeric immunoglobulin receptor deficiency. Nat. Commun. 7, 11240 (2016).
Druzhinin, V. G. et al. Sputum microbiota in coal workers diagnosed with pneumoconiosis as revealed by 16s rRNA gene sequencing. Life 12, 830 (2022).
Huang, Y. J. et al. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J. Clin. Microbiol. 52, 2813–2823 (2014).
Pamer, E. G. Resurrecting the intestinal microbiota to combat antibiotic-resistant pathogens. Science 352, 535–538 (2016).
Roquilly, A. et al. Hydrocortisone therapy for patients with multiple trauma: the randomized controlled hypolyte study. JAMA 305, 1201–1209 (2011).
Asehnoune, K. et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (corti-tc): a double-blind, multicentre phase 3, randomised placebo-controlled trial. Lancet Respir. Med. 2, 706–716 (2014).
Lee, S. E., Eick, A., Bloom, M. S. & Brundage, J. F. Influenza immunization and subsequent diagnoses of group a streptococcus-illnesses among u.S. Army trainees, 2002-2006. Vaccine 26, 3383–3386 (2008).
Bentley, D. R. et al. Accurate whole human genome sequencing using reversible terminator chemistry. Nature 456, 53–59 (2008).
Voskoboynik, A. et al. The genome sequence of the colonial chordate, botryllus schlosseri. Elife 2, e00569 (2013).
Allali, I. et al. A comparison of sequencing platforms and bioinformatics pipelines for compositional analysis of the gut microbiome. BMC Microbiol. 17, 194 (2017).
Albert, R. K. et al. Azithromycin for prevention of exacerbations of copd. N. Engl. J. Med. 365, 689–698 (2011).
Wong, C. et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (embrace): a randomised, double-blind, placebo-controlled trial. Lancet 380, 660–667 (2012).
Saiman, L. et al. Azithromycin in patients with cystic fibrosis chronically infected with pseudomonas aeruginosa: a randomized controlled trial. JAMA 290, 1749–1756 (2003).
Toh, Z. Q., Anzela, A., Tang, M. L. & Licciardi, P. V. Probiotic therapy as a novel approach for allergic disease. Front. Pharm. 3, 171 (2012).
Popova, M. et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J. Appl. Microbiol. 113, 1305–1318 (2012).
Mortaz, E. et al. Anti-inflammatory effects of lactobacillus rahmnosus and bifidobacterium breve on cigarette smoke activated human macrophages. PLoS ONE 10, e0136455 (2015).
Sivan, A. et al. Commensal bifidobacterium promotes antitumor immunity and facilitates anti-pd-l1 efficacy. Science 350, 1084–1089 (2015).
Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Backhed, F. From dietary fiber to host physiology: short-chain fatty acids as key bacterial metabolites. Cell 165, 1332–1345 (2016).
Fukuda, S. et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature 469, 543–547 (2011).
Furusawa, Y. et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory t cells. Nature 504, 446–450 (2013).
Donohoe, D. R. et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab. 13, 517–526 (2011).
Macia, L. et al. Metabolite-sensing receptors gpr43 and gpr109a facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome. Nat. Commun. 6, 6734 (2015).
Vinolo, M. A. et al. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J. Nutr. Biochem. 22, 849–855 (2011).
Leitao Filho, F. S. et al. Sputum microbiome is associated with 1-year mortality after chronic obstructive pulmonary disease hospitalizations. Am. J. Respir. Crit. Care Med. 199, 1205–1213 (2019).
Rogers, G. B. et al. A novel microbiota stratification system predicts future exacerbations in bronchiectasis. Ann. Am. Thorac. Soc. 11, 496–503 (2014).
Bosch, A. et al. Maturation of the infant respiratory microbiota, environmental drivers, and health consequences. A prospective cohort study. Am. J. Respir. Crit. Care Med. 196, 1582–1590 (2017).
Sibila, O. et al. Airway bacterial load and inhaled antibiotic response in bronchiectasis. Am. J. Respir. Crit. Care Med. 200, 33–41 (2019).
Combs, M. P. et al. Lung microbiota predict chronic rejection in healthy lung transplant recipients: a prospective cohort study. Lancet Respir. Med. 9, 601–612 (2021).
Dickson, R. P. The microbiome and critical illness. Lancet Respir. Med. 4, 59–72 (2016).
Metheny, N. A. et al. Tracheobronchial aspiration of gastric contents in critically ill tube-fed patients: frequency, outcomes, and risk factors. Crit. Care Med. 34, 1007–1015 (2006).
Zakharkina, T. et al. The dynamics of the pulmonary microbiome during mechanical ventilation in the intensive care unit and the association with occurrence of pneumonia. Thorax 72, 803–810 (2017).
Roy, S. & Trinchieri, G. Microbiota: a key orchestrator of cancer therapy. Nat. Rev. Cancer 17, 271–285 (2017).
Hosgood, H. D. 3rd et al. The potential role of lung microbiota in lung cancer attributed to household coal burning exposures. Environ. Mol. Mutagen 55, 643–651 (2014).
Jin, J. et al. Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: a multiple comparative study design with independent validation. Lung Cancer 136, 129–135 (2019).
Barfod, K. K. et al. The murine lung microbiome changes during lung inflammation and intranasal vancomycin treatment. Open Microbiol. J. 9, 167–179 (2015).
Morozova, V. V., Vlassov, V. V. & Tikunova, N. V. Applications of bacteriophages in the treatment of localized infections in humans. Front. Microbiol. 9, 1696 (2018).
Yi, X., Gao, J. & Wang, Z. The human lung microbiome—a hidden link between microbes and human health and diseases. iMeta 1, e33 (2022).
Fromentin, M., Ricard, J. D. & Roux, D. Respiratory microbiome in mechanically ventilated patients: a narrative review. Intensive Care Med. 47, 292–306 (2021).
Zinter, M. S. et al. Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates. Sci. Transl. Med. 14, eabm8646 (2022).
Watzenboeck, M. L. et al. Multi-omics profiling predicts allograft function after lung transplantation. Eur. Respir. J. 59, 2003292 (2022).
Chotirmall, S. H. et al. Therapeutic targeting of the respiratory microbiome. Am. J. Respir. Crit. Care Med. 206, 535–544 (2022).
Salter, S. J. et al. Reagent and laboratory contamination can critically impact sequence-based microbiome analyses. BMC Biol. 12, 87 (2014).
Leitao Filho, F. S. et al. Effects of inhaled corticosteroid/long-acting beta(2)-agonist combination on the airway microbiome of patients with chronic obstructive pulmonary disease: a randomized controlled clinical trial (disarm). Am. J. Respir. Crit. Care Med. 204, 1143–1152 (2021).
Gomes, S. et al. Profiling of lung microbiota discloses differences in adenocarcinoma and squamous cell carcinoma. Sci. Rep. 9, 12838 (2019).
Clark, J. A. et al. Rapid assay for sick children with acute lung infection study (rascals): diagnostic cohort study protocol. BMJ Open 11, e056197 (2021).
